Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939131 · ClinicalTrials.gov registry record · NA
IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV
A NA study, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- Completed
- Registry status
- NA
- Development phase
- 156
- Enrollment target
NCT02939131: Completed NA study, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
NCT02939131 is a NA study that has completed, run by International Maternal Pediatric Adolescent AIDS Clinical Trials Group. The registered enrollment target is 156 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02939131, a NA study, has completed, sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 156 participants
- Enrollment target
Study Summary
IMPAACT 2002 is a prospective, multi-site, two-arm, cluster-randomized study to evaluate whether a health and wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention for depression demonstrates improved depression and medical outcomes for HIV-infected youth in the United States (US) compared to enhanced standard care (ESC).
Primary Outcome
The QIDS-SR ranges from 0-27 and assesses the severity and number of depression symptoms. Data completed through the Audio Computer Assisted Interview (ACASI) system are used for this outcome. A lower score indicates fewer depression symptoms and lower depression symptom severity. Scores for all participants at a site were averaged. The site-specific averages were then analyzed.
Interventions
- BEHAVIORAL Enhanced Standard of Care
- BEHAVIORAL Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2020-01-21 |
| Phase | NA |
What the finished NCT02939131 record still lists
NCT02939131 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Enhanced Standard of Care is the first listed.
NCT02939131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02939131 about?
NCT02939131 is a clinical study titled "IMPAACT 2002: Cognitive Behavioral Therapy and Medication Management for Treatment of Depression in US Youth With HIV". IMPAACT 2002 is a prospective, multi-site, two-arm, cluster-randomized study to evaluate whether a health and wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention for depression demonstrates improved depression and medical outcomes for HIV-infected youth in the Unite...
What is the current status of trial NCT02939131?
This trial is currently completed. It is a NA study. The enrollment target is 156 participants. The study started on 2017-03-06. Estimated completion is 2020-01-21.
What interventions are being tested in trial NCT02939131?
The interventions under investigation include: Enhanced Standard of Care (BEHAVIORAL), Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm (BEHAVIORAL).
Who is sponsoring clinical trial NCT02939131?
This trial is sponsored by International Maternal Pediatric Adolescent AIDS Clinical Trials Group, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02939131's enrollment target sits among peer trials
156 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI